Hanall Biopharma Co Ltd 009420
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 009420 is a good fit for your portfolio.
News
-
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease
-
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update
-
HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- KRW 35,150.00
- Day Range
- KRW 35,650.00–37,650.00
- 52-Week Range
- KRW 18,400.00–46,750.00
- Bid/Ask
- KRW 36,600.00 / KRW 36,800.00
- Market Cap
- KRW 1.85 Tril
- Volume/Avg
- 728,216 / 576,941
Key Statistics
- Price/Earnings (Normalized)
- 495.31
- Price/Sales
- 13.21
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 312
- Website
- http://www.hanall.co.kr
Comparables
Valuation
Metric
|
009420
|
016580
|
039200
|
---|---|---|---|
Price/Earnings (Normalized) | 495.31 | 7.40 | — |
Price/Book Value | 9.86 | 0.62 | 11.66 |
Price/Sales | 13.21 | 0.96 | 233.28 |
Price/Cash Flow | 188.35 | 5.65 | — |
Price/Earnings
009420
016580
039200
Financial Strength
Metric
|
009420
|
016580
|
039200
|
---|---|---|---|
Quick Ratio | 2.10 | 3.93 | 2.86 |
Current Ratio | 3.02 | 5.30 | 2.94 |
Interest Coverage | 31.93 | 1,345.19 | −90.11 |
Quick Ratio
009420
016580
039200
Profitability
Metric
|
009420
|
016580
|
039200
|
---|---|---|---|
Return on Assets (Normalized) | 2.24% | 7.92% | −20.27% |
Return on Equity (Normalized) | 2.90% | 8.87% | −25.17% |
Return on Invested Capital (Normalized) | 2.31% | 7.89% | −26.91% |
Return on Assets
009420
016580
039200
Drug Manufacturers - Specialty & Generic Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Zfhxrplf | Khtzx | $79.1 Bil | |
MKKGY
| Merck KGaA ADR | Qcklzrfg | Mzwlrm | $74.3 Bil | |
HLN
| Haleon PLC ADR | Ljczwrtxl | Hyr | $38.1 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Jvnxztpv | Vdqgs | $19.1 Bil | |
VTRS
| Viatris Inc | Cnhzlbx | Ssfm | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Bdmggfk | Wdgkp | $11.7 Bil | |
CTLT
| Catalent Inc | Ynrlplq | Kklxwy | $10.0 Bil | |
CURLF
| Curaleaf Holdings Inc | Ggjjtkwmv | Gbkjr | $4.2 Bil | |
PRGO
| Perrigo Co PLC | Swnvdvwk | Ybx | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Gtcghlz | Wnzsxm | $3.3 Bil |